Only about a month after entering the nasal delivery device market, Bespak has announced a second contract for development of an intranasal device. The company says that “a major global manufacturer of generic medicines” has awarded Bespak a contract for both development of its Unidose nasal drug delivery device for an undisclosed application and for manufacturing and filling of the device once it launches, which is expected to take place in 2015.
Jon Glenn, CEO of Consort Medical, parent company of Bespak commented, “Our Cambridge Innovations Centre is clearly delivering a portfolio of products that leverages our competencies and our technology in adjacent market spaces. This is the second nasal development contract that Bespak has been awarded, and successfully demonstrates our strategy to diversify into new drug delivery markets. In addition, we are moving up the value chain by adding drug filling to our list of competencies.”
Read the Consort Medical press release.
